Toleranzia AB Cash Flow Conversion Efficiency
Toleranzia AB cash flow conversion efficiency. Based on the latest financial reports, Toleranzia AB (TOL) has a cash flow conversion efficiency ratio of -0.023x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.98 Million ≈ $-428.10K USD) by net assets (Skr173.87 Million ≈ $18.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Toleranzia AB (2014–2024)
Cash flow conversion efficiency of Toleranzia AB from 2014 to 2024. This chart illustrates how Toleranzia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Toleranzia AB (TOL) share price today for real-time trading data and today's change.
Toleranzia AB Cash Flow Conversion Ratio Explained
Toleranzia AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Toleranzia AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Toleranzia AB ranked by their cash flow conversion efficiency. Also see how much is Toleranzia AB worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vaswani Industries Limited
NSE:VASWANI
|
0.072x |
|
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
|
-0.084x |
|
GigaMedia Limited
F:GIFN
|
N/A |
|
Firefly Neuroscience, Inc.
NASDAQ:AIFF
|
-0.154x |
|
123fahrschule SE
DU:123F
|
-0.004x |
|
Auking Mining Ltd
AU:AKN
|
-0.199x |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
-1.155x |
|
Vertice Bhd
KLSE:7240
|
0.051x |
Annual Cash Flow Conversion Efficiency for Toleranzia AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of Toleranzia AB from 2014 to 2024. Review TOL cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr180.07 Million ≈ $19.38 Million |
Skr-10.28 Million ≈ $-1.11 Million |
-0.057x | -38.60% |
| 2023-12-31 | Skr153.52 Million ≈ $16.52 Million |
Skr-6.32 Million ≈ $-680.46K |
-0.041x | +31.64% |
| 2022-12-31 | Skr119.51 Million ≈ $12.86 Million |
Skr-7.20 Million ≈ $-774.83K |
-0.060x | -12.56% |
| 2021-12-31 | Skr127.97 Million ≈ $13.77 Million |
Skr-6.85 Million ≈ $-737.10K |
-0.054x | +8.91% |
| 2020-12-31 | Skr67.92 Million ≈ $7.31 Million |
Skr-3.99 Million ≈ $-429.53K |
-0.059x | +53.62% |
| 2019-12-31 | Skr34.99 Million ≈ $3.77 Million |
Skr-4.43 Million ≈ $-477.06K |
-0.127x | +27.53% |
| 2018-12-31 | Skr27.59 Million ≈ $2.97 Million |
Skr-4.82 Million ≈ $-519.03K |
-0.175x | +54.26% |
| 2017-12-31 | Skr14.67 Million ≈ $1.58 Million |
Skr-5.61 Million ≈ $-603.27K |
-0.382x | -46.00% |
| 2016-12-31 | Skr20.06 Million ≈ $2.16 Million |
Skr-5.25 Million ≈ $-565.11K |
-0.262x | -90.44% |
| 2015-12-31 | Skr24.45 Million ≈ $2.63 Million |
Skr-3.36 Million ≈ $-361.73K |
-0.137x | +74.75% |
| 2014-12-31 | Skr1.72 Million ≈ $184.88K |
Skr-935.22K ≈ $-100.65K |
-0.544x | -- |
About Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more